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Summary
Background The completion of poliomyelitis eradication is a global emergency for public health. In 2012, more than 
50% of the world’s cases occurred in Nigeria following an unanticipated surge in incidence. We aimed to quantitatively 
analyse the key factors sustaining transmission of poliomyelitis in Nigeria and to calculate clinical eﬃ  cacy estimates 
for the oral poliovirus vaccines (OPV) currently in use.
Methods We used acute ﬂ accid paralysis (AFP) surveillance data from Nigeria collected between January, 2001, and 
December, 2012, to estimate the clinical eﬃ  cacies of all four OPVs in use and combined this with vaccination coverage 
to estimate the eﬀ ect of the introduction of monovalent and bivalent OPV on vaccine-induced serotype-speciﬁ c 
population immunity. Vaccine eﬃ  cacy was determined using a case-control study with CIs based on bootstrap 
resampling. Vaccine eﬃ  cacy was also estimated separately for north and south Nigeria, by age of the children, and by 
year. Detailed 60-day follow-up data were collected from children with conﬁ rmed poliomyelitis and were used to 
assess correlates of vaccine status. We also quantitatively assessed the epidemiology of poliomyelitis and programme 
performance and considered the reasons for the high vaccine refusal rate along with risk factors for a given local 
government area reporting a case. 
Findings Against serotype 1, both monovalent OPV (median 32·1%, 95% CI 26·1–38·1) and bivalent OPV (29·5%, 
20·1–38·4) had higher clinical eﬃ  cacy than trivalent OPV (19·4%, 16·1–22·8). Corresponding data for serotype 3 were 
43·2% (23·1–61·1) and 23·8% (5·3–44·9) compared with 18·0% (14·1–22·1). Combined with increases in coverage, 
this factor has boosted population immunity in children younger than age 36 months to a record high (64–69% 
against serotypes 1 and 3). Vaccine eﬃ  cacy in northern states was estimated to be signiﬁ cantly lower than in southern 
states (p≤0·05). The proportion of cases refusing vaccination decreased from 37–72% in 2008 to 21–51% in 2012 for 
routine and supplementary immunisation, and most caregivers cited ignorance of either vaccine importance or 
availability as the main reason for missing routine vaccinations (32·1% and 29·6% of cases, respectively). Multiple 
regression analyses highlighted associations between the age of the mother, availability of OPV at health facilities, 
and the primary source of health information and the probability of receiving OPV (all p<0·05).
Interpretation Although high refusal rates, low OPV campaign awareness, and heterogeneous population immunity 
continued to support poliomyelitis transmission in Nigeria at the end of 2012, overall population immunity had 
improved due to new OPV formulations and improvements in programme delivery.
Funding Bill & Melinda Gates Foundation Vaccine Modeling Initiative, Royal Society.
Introduction
In May, 2012, after more than 20 years of mass vaccination 
campaigns, the 65th World Health Assembly declared 
that the completion of poliomyelitis eradication was a 
“programmatic emergency for global public health”.1 
Substantial ﬁ nancial and political pledges to poliomyelitis 
eradication have recently reintensiﬁ ed eﬀ orts, and 
prevalence of poliomyelitis is at a historical low, although 
transmission in Afghanistan, Pakistan, and Nigeria 
remains persistent. Globally, case numbers have fallen 
(1651 cases in 2008 vs 223 in 2012), and India, once one of 
the most entrenched reservoirs, is now free of indigenous 
poliovirus transmission.2 However, in Nigeria, polio-
myelitis cases doubled between 2011 and 2012, with 
sustained transmission of all three serotypes in 2012 
(103 and 19 cases due to serotypes 1 and 3 wild poliovirus 
and eight due to circulating vaccine-derived poliovirus 
type 2 [cVDPV2]).2,3 In 2012, Nigeria was the global 
epicentre of poliovirus outbreaks, astonishing those who 
commended its success during 2010 when case numbers 
fell by 95%.4 
The 2011 Nigeria Emergency Action Plan has been 
reﬁ ned to further involve key political and traditional 
leaders, and hundreds of volunteer community 
mobilisers have been charged with reaching every child 
in Nigeria to administer the vaccines to combat the 
recent setbacks.5 The 2012 plan built on lessons learnt in 
previous years, aiming to integrate almost real-time 
feedback from teams on the ground with the highest 
level of governance to ensure chronically missed children 
are protected and supplies reach the most vulnerable 
children.6 Additionally, in November, 2009, the Advisory 
Committee on Poliomyelitis Eradication recommended 
the introduction of bivalent oral poliovirus vaccine 
(bOPV) to supplementary immunisation activities in 
areas with sustained transmission of wild-type poliovirus 
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serotypes 1 and 3, but the eﬃ  cacy of bOPV in Nigeria has 
not yet been assessed.7 Such an assessment is especially 
important during this period of rapid increase in demand 
and manufacture of the vaccine and when discussions 
are underway regarding its potential use during routine 
immunisation in place of trivalent vaccine (tOPV).8
In this Article we explain why Nigeria has been 
experiencing continued high caseloads despite achieving 
record successes in vaccine coverage and political and 
community engagement by identifying the key factors 
driving poliovirus transmission. 
Methods
Study design and procedures
We used acute ﬂ accid paralysis (AFP) surveillance data 
from Nigeria collected between January, 2001, and 
December, 2012, to estimate the clinical eﬃ  cacies of all 
four oral poliovirus vaccines (OPVs) using a case-control 
study. This was combined with vaccination coverage to 
estimate the eﬀ ect of the introduction of monovalent 
OPV (mOPV) and bOPV on vaccine-induced serotype-
speciﬁ c population immunity.
To assess eﬃ  cacy, children aged under 15 years with 
conﬁ rmed poliomyelitis (due to wild-type 1 or 3 poliovirus 
or cVDPV2) were matched with up to ﬁ ve randomly 
selected control children with non-poliomyelitis AFP 
chosen from the AFP surveillance database produced by 
the government of Nigeria (appendix). Cases were 
matched to controls by state and by date (within 1 month) 
and age at onset of paralysis (within 6 months). These 
criteria were chosen to maximise the number of matches 
while controlling for diﬀ erential exposure to poliovirus. 
Vaccine eﬃ  cacy was also estimated separately for north 
and south Nigeria, by age of the children, and by year.
To investigate vaccine-induced population immunity, 
we estimated the proportion of children younger than 
36 months who were protected against each poliovirus 
serotype, on the basis of the reported vaccination history 
of children with non-poliomyelitis AFP and our estimates 
of vaccine eﬃ  cacy. These children were assumed to be 
representative of the underlying population. Detailed 
60-day follow-up data were collected from children with 
conﬁ rmed poliomyelitis and were used to assess 
correlates of vaccine status.
Finally, we quantitatively assessed the epidemiology of 
poliomyelitis and programme performance and 
considered the reasons for the high vaccine refusal rate 
along with risk factors for a given local government area 
(LGA) reporting a case.
Institutional ethics approval was not sought because 
this is a retrospective study using anonymised national 
surveillance data detailing the use of standard vaccines 
licensed by the National Regulatory Authority of the 
Government of Nigeria.
Statistical analysis
We assumed that all vaccines were received through 
supplementary immunisation activities, because the 
database does not distinguish between routine 
vaccinations or supplementary immunisation activities. 
We used  bootstrap resampling methods to minimise the 
eﬀ ect of outliers and bias introduced by the matching 
process. Vaccine eﬃ  cacy was estimated by con ditional 
logistic regression for 1000 randomly matched sets, 
producing a distribution of estimates for each vaccine 
type. 95% CIs (2·5th and 97·5th percentiles of 
bootstrapped estimates) around the median estimate 
represent the uncertainty introduced by the matching 
criteria. Sensitivity of the vaccine eﬃ  cacy estimates to the 
matching criteria was examined and the analysis was 
repeated under the assumption that the ﬁ rst three doses 
received were through routine immunisation (ie, tOPV) 
and the remainder via supplementary immunisation 
activities. The prevalence of non-poliomyelitis entero-
viruses by region was examined and compared by the 
Fisher’s exact test.
The probability of vaccine-induced immunity in each 
child was estimated on the basis of the number of doses 
of each OPV type received and a randomly sampled value 
for the eﬃ  cacy of each OPV using the range of estimates 
from the case-control study and accounting for covariance 
of the estimates. The mean of this quantity for children 
with non-poliomyelitis AFP was calculated and weighted 
by age to match the age distribution of the population. 
 Type 1 Type 2 Type 3
tOPV mOPV1 bOPV tOPV tOPV mOPV3 bOPV
All states
 No routine coverage 19·4% (16·1 to 22·8) 32·1%* (26·1 to 38·1) 29·5%* (20·1 to 38·4) 48·5% (43·1 to 53·1) 18·0% (14·1 to 22·1) 43·2%* (23·1 to 61·1) 23·8% (5·3 to 44·9)
100% routine coverage 21·1% (18·2 to 24·0) 36·0%* (24·7 to 47·0) 24·2% (12·1 to 37·4) 22·0% (19·5 to 25·3) 17·6% (13·8 to 21·4) 40·4% (–0·2 to 66·0) 25·1% (3·7 to 54·1)
Northern states 19·2% (15·8 to 22·7) 28·8%* (21·9 to 35·6) 29·9%* (20·4 to 38·9) 48·9% (43·4 to 53·2) 17·7% (13·5 to 21·9) 40·9% (16·7 to 63·0) 24·0% (5·3 to 45·4)
Southern states 35·6%† (21·1 to 56·9) 52·5%† (40·4 to 65·2) NA NA 40·9% (3·9 to 68·3) 58·2% (20·4 to 85·1) NA
Data are median values from the distribution of vaccine eﬃ  cacy estimates with 95% CIs (2·5th and 97·5th percentile intervals) derived from conditional logistic regression on 1000 matched sets. Controls were 
matched to cases by date of onset (within 1 month), age at onset (within 6 months), and state. Estimates for vaccine eﬃ  cacy in north and south Nigeria use the assumption of no routine coverage. 
mOPV=monovalent oral poliovirus vaccine. bOPV=bivalent oral poliovirus vaccine. tOPV=trivalent oral poliovirus vaccine. NA=not applicable. *p<0·05 compared with tOPV estimate.  †p≤0·05 compared with 
northern states estimate. 
Table 1: Estimated eﬃ  cacy of one dose of trivalent oral poliovirus vaccine, serotype 1 or 3 monovalent oral poliovirus vaccine, and bivalent oral poliovirus vaccine 
See Online for appendix
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We present median estimates and intervals on the basis 
of the 2·5th and 97·5th percentiles of the distribution 
from 1000 bootstrap replicates (95% CIs).
We used logistic regression to estimate the association 
between OPV vaccination status and the socioeconomic 
background of cases, the primary source of health 
information, and provision of local health facilities. We 
also examined the reported individual reasons for 
children with poliomyelitis to miss OPV doses during 
routine or supplementary immunisation.
To assess the risk of a LGA reporting a poliomyelitis 
case, we used an over-dispersed Poisson mixed-eﬀ ects 
model that incorporated the spatial and temporal 
pseudoreplication of our data (ie, data are nested within 
LGAs and LGAs are repeatedly measured over time). The 
minimum model was calculated using a backwards 
stepwise deletion process with Akaike’s information 
criterion, and explanatory variables were retained in the 
model if they were signiﬁ cant (p<0·05) or reduced the 
Akaike’s information criterion value. Variables examined 
in the model include poliomyelitis incidence within 50 km 
of the centrepoint of the LGA, population immunity, and 
population density (calculated using the area and 
population size).9 Spatial resolution was ﬁ xed at the LGA 
level and variables were calculated over 12-month intervals.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Bootstrapped bOPV eﬃ  cacy estimates were higher than 
the corresponding tOPV estimates in 97·9% of models 
(p=0·04) assuming no routine coverage and 66·7% of 
models (p=0·7) assuming 100% coverage (table 1). There 
were no signiﬁ cant diﬀ erences between bOPV and 
mOPV1 or mOPV3 under either assumption (all p>0·1). 
The lower tOPV eﬃ  cacy against serotype 2 assuming 
100% routine coverage compared with no routine 
coverage is a result of the higher number of doses 
received by children with poliomyelitis under this 
assumption compared with no routine coverage, which 
drives down the per-dose eﬃ  cacy estimate. Adjustment 
of the matching criteria did not alter the general ﬁ nding 
of lower tOPV eﬃ  cacy compared with mOPV (appendix). 
There was no improvement in model ﬁ t when vaccine 
eﬃ  cacy was assessed by age (likelihood ratio test for each 
matched set for serotype 1 median p=0 ·28, 95% CI 
0·01–0·88; serotype 3 p=0·21, 0·01–0·81; and 
cVDPV2 p=0·07, 0·01–0·29) or year of onset 
(serotype 1 p=0·07, 0·001–0·64; serotype 3 p=0·60, 
0·04–0·97; and cVDPV2 p=0·25, 0·03–0·68; appendix). 
When eﬃ  cacy was assessed by region, the model ﬁ t for 
serotype 1 improved (median p=0·03, 95% CI 
Figure 1: Eﬀ ects of oral poliovirus vaccine use on poliomyelitis during 2001–12
(A) Monthly incidence of poliomyelitis associated with serotypes 1 and 3 wild poliovirus and cVDPV2. (B) Median 
estimated age-standardised vaccine-induced population immunity against poliomyelitis due to serotype 1, 
serotype 3, and cVDPV2 poliovirus on the basis of vaccination histories of children younger than 36 months with 
non-poliomyelitis AFP by year of onset of paralysis. Estimates not standardised to show geographic population 
distribution and therefore biased towards areas with a high incidence of non-poliomyelitis AFP. Bars=2·5th and 
97·5th percentile intervals (95% CIs) based on bootstrap resampling. (C) Mean numbers of doses of OPV received 
by children younger than 36 months with non-poliomyelitis AFP, age-standardised to match underlying 
demography. Plot shows estimates under the assumption that all OPV doses were received via SIAs. Arrows depict 
timings of SIAs, with length of arrows proportional to number of local government areas that participated. 
AFP=acute ﬂ accid paralysis. bOPV=bivalent oral poliovirus vaccine. cVDPV2=circulating vaccine-derived poliovirus 
type 2. mOPV= monovalent oral poliovirus vaccine. OPV=oral poliovirus vaccine. SIA=supplementary 
immunisation activity. tOPV=trivalent oral poliovirus vaccine.
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0·0003–0·40), with a higher estimated eﬃ  cacy in the 
south than the north for tOPV and mOPV1 in 97·5–100% 
of matched sets (both p≤0·05). A higher prevalence of 
enteroviruses was found in north than in south Nigeria 
(odds ratio 0·60, 95% CI 0·57–0·64 p<0·0001, Fisher’s 
exact test).
After the introduction of bOPV in 2009, the incidence 
of poliomyelitis fell substantially (ﬁ gure 1A), and the 
proportion of children in Nigeria with vaccine-induced 
immunity against poliovirus was at its highest in 2012, 
reaching 64–69% against serotypes 1 and 3 (ﬁ gure 1B). 
The advances in immunity were driven by the more 
eﬀ ective mOPV and bOPV formulations introduced in 
2005 and 2009, respectively, along with an increase in the 
overall number of doses reported (mean 5·6 doses 
[SD 3·5] in 2012 vs 3·9 [2·2] in 2009; ﬁ gure 1C). AFP 
surveillance sensitivity consistently exceeded the 
recommended minimum of one reported case annually 
per 100 000 children and has progressively improved 
(data not shown). Immunity in children younger than 
36 months within the high-risk states (deﬁ ned by the 
2012 Nigeria Polio Eradication Emergency Plan)6 was 
heterogeneous in 2012 and 60 (20%) of 297 LGAs still 
had fewer than 50% of children protected against 
poliomyelitis (ﬁ gure 2).
Caregiver refusal of vaccination became less common 
as a reason for children with poliomyelitis to miss OPV 
doses, although rates remained high (21·0% for routine 
and 50·9% for supplementary immunisation activities in 
2012; ﬁ gure 3). The main reported reasons for missing 
routine OPV doses in 2012 were an ignorance of vaccine 
importance or vaccine availability (32·1% and 29·6% of 
cases, respectively). In 2012, 21 (24·1%) of the 
87 conﬁ rmed cases with a known vaccination history 
listed in the follow-up database had received no OPV. 
Multiple logistic regression revealed signiﬁ cant 
associations between the mother’s age, OPV availability 
at the nearest health facility, primary source of health 
information, and year of onset of paralysis with the 
probability of a case receiving OPV (all p<0·05; table 2). A 
nomadic lifestyle was not signiﬁ cantly associated with a 
failure to vaccinate (p=0·88; appendix). To further explore 
Figure 2: Serotype-speciﬁ c vaccine-induced immunity by local government area in Nigeria and the spatial distribution of poliomyelitis cases during 2012
(A–C) Serotype-speciﬁ c vaccine-induced immunity by LGA in Nigeria. LGAs with no shading had insuﬃ  cient numbers of non-poliomyelitis AFP cases during 2012 to 
estimate population immunity. (D) Spatial distribution of poliomyelitis cases. Each poliomyelitis case is represented by one triangle, randomly placed within the LGA of 
residence. The 12 high-risk states published by the National Primary Health Care Development Agency of Nigeria are highlighted in green.6 AFP=acute ﬂ accid paralysis. 
cVDPV2=circulating vaccine-derived poliovirus type 2. LGA=local government area. 
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this factor, we examined variables concerning the 
presence of a nomadic camp within 5 km of the 
household, whether the family live in a permanent 
structure, and in how many diﬀ erent locations the child 
had lived during the past 12 months as proxy measures of 
a nomadic or semi-nomadic lifestyle. None of these 
variables was signiﬁ cantly associated with children with 
poliomyelitis receiving OPV (appendix).
We found associations between poliomyelitis incidence 
and estimated population immunity along with the 
presence of a case within 50 km (appendix). Present 
immunity within each LGA had the strongest protective 
eﬀ ect against incidence (rate ratio 0·49, 95% CI 0·37–0·64), 
and the presence of cases within the past 12 months 
marginally decreased risk (0·93, 0·91–0·96; appendix).
Discussion
In this study, we show that the persistence of poliovirus 
in northern Nigeria is driven by three fundamental 
issues: ﬁ rst, vaccine eﬃ  cacy seems to be lower in 
northern states compared with southern states; second, 
coverage and population immunity remain too low to 
interrupt wild poliovirus transmission; and third, despite 
huge investments in communication, refusals and 
unawareness of vaccine availability or importance still 
dominate as reasons for failing to immunise children 
who develop poliomyelitis (panel).
The higher eﬃ  cacy of bOPV compared with tOPV 
against poliomyelitis due to serotype 1, with the 
assumption of no routine coverage, suggests that a pre-
eradication switch from tOPV to bOPV for routine 
immunisation, as part of the broader poliomyelitis 
endgame strategy, could also facilitate faster eradication 
of serotype 1 wild-type polioviruses.15 The recom-
mendation by the Global Polio Eradication Initiative15 for 
bOPV introduction in supplementary immunisation 
activities was made on the basis of a study in India,11 
which showed non-inferior immunogenicity of bOPV 
compared with monovalent vaccines, and our data 
support this ﬁ nding. Our tOPV eﬃ  cacy estimates are 
consistent with those from previous studies in Nigeria, 
although we found a lower mOPV eﬃ  cacy against 
poliomyelitis due to serotype 1.10,16 This ﬁ nding might be 
a result of errors in inferring a child’s vaccination history, 
particularly after a vaccine has been used in a large 
number of campaigns over a substantial period, as is the 
case for mOPV. Nonetheless, the monovalent vaccines 
showed a consistently higher eﬃ  cacy than tOPV for each 
serotype, in agreement with ﬁ ndings from earlier 
studies.17,18 Our countrywide estimates of tOPV eﬃ  cacy 
are comparable with those found in Bihar, India, where 
poliomyelitis has been successfully eliminated despite 
high population density and poor sanitation.19
Our ﬁ nding of poor vaccine eﬃ  cacy in the north of 
Nigeria might be a result of a higher incidence of enteric 
infections, including other enteroviruses, which might 
interfere with the response to the vaccine.20,21 Vaccine 
eﬃ  cacy estimates could also be more substantially aﬀ ected 
in the north by inaccurate vaccination histories, in view of 
the frequent rounds of supplementary immunisation 
activities with diﬀ ering vaccine types. However, OPV 
eﬃ  cacy (regardless of type) was signiﬁ cantly lower in the 
north (appendix), and weak evidence of lower tOPV 
eﬃ  cacy against serotype 1 poliomyelitis in north Nigeria 
has been reported previously (northern region 13–23%, 
95% CI 1–40; southern region 54%, 4–78%).10 Low OPV 
eﬃ  cacy would necessitate a higher number of doses to 
achieve eradication and would support the accelerated 
 Figure 3: Reported reasons for missing oral poliovirus vaccine doses from routine and supplementary 
immunisation programmes between 2006 and 2012
Few data exist for routine immunisation during 2011 and so this year has been excluded. Data were obtained from 
the 60-day follow-up examinations and comprise only conﬁ rmed paralytic poliomyelitis cases. Numbers of 
observations are given above the bars (in the lower ﬁ gure, reasons for children missing up to eight supplementary 
immunisation rounds are recorded).
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introduction of inactivated poliovirus vaccine in high-risk 
areas to boost immunity to all three serotypes (as outlined 
in the endgame strategy).15
The principal reason for children with poliomyelitis to 
miss routine immunisations was an ignorance of its 
importance, reaﬃ  rming the recommendations made by 
the Independent Monitoring Board of the Global Polio 
Eradication Initiative that promotion of demand 
generation is vital to eradication.22 The primary source of 
information on health issues strongly aﬀ ected an 
individual’s probability of receiving OPV and so should 
be a priority for eradication programmes. The strong 
link between receiving OPV and obtaining health 
education via town announcers has been previously 
recognised and used as a way of promoting a positive 
message about vaccination.14,23 In Pakistan and 
Afghanistan, where vaccine eﬃ  cacy estimates are 
comparable with Nigeria, targeted social mobilisation 
activities aimed at improving community perceptions 
have seen great success in reducing cases by 66% 
between 2011 and 2012.2,12,24 The availability of 
immunisation via the routine Expanded Programme on 
Immunization also aﬀ ected the likelihood of receiving 
OPV, although distance to the nearest health facility was 
non-signiﬁ cant (p=0·40), probably because the 
supplementary immunisation activity teams undertook 
house-to-house visits. Our analysis included only those 
with conﬁ rmed poliomyelitis, and factors driving vaccine 
acceptance in cases might diﬀ er from those aﬀ ecting the 
wider population. However understanding vaccine 
perceptions in these high-risk groups is clearly important 
for the eradication programme. Additionally, we expect 
that outreach programmes promoting routine 
immunisation (requiring caregivers to actively attend 
health facilities) might diﬀ er from those promoting 
supplementary immunisation activities (in which teams 
of health workers visit any dwellings with children), and 
this important topic needs further study.
Although a commonly cited reason for missing 
children is the nomadic lifestyle of their families,25 our 
ﬁ ndings suggest that this factor might not be as 
important as ﬁ rst thought; few cases reported here claim 
to be nomadic and a nomadic lifestyle was not associated 
with a failure to vaccinate. Children of nomadic families 
might be less likely to visit a health facility and therefore 
be included in the database, but the clinical symptoms of 
poliomyelitis are suﬃ  ciently severe that we would expect 
most families to seek help.
Our results are reliant on accurate reporting of dose 
numbers. A more detailed vaccination history obtained 
at the 60-day follow-up for a subset of poliomyelitis cases 
agreed well with initial reports, with no suggestion of 
over-reporting or under-reporting of total dose numbers 
(appendix). The routine coverage assumptions we used 
represent two extreme scenarios; the true coverage level 
is heterogeneous across the population. However, the 
ﬁ ndings are robust to these assumptions—ie, mOPV 
Odds ratio (95% CI) p value
Age of mother 1·03 (1·00–1·06) 0·041
Number of children 0·96 (0·92–1·01) 0·129
Nearest health facility oﬀ ering EPI 1·85 (1·09–3·07) 0·019
Primary source health information
No information 1·0 ··
Village or community 2·33 (0·57–9·14) 0·223
Traditional leader 2·27 (0·56–8·89) 0·239
Health worker 5·37 (1·51–17·90) 0·006
Media (radio/TV) 2·41 (0·68–7·92) 0·149
Town announcer 9·46 (2·47–34·63) 0·001
Relatives 2·92 (0·62–14·22) 0·172
Religious leader 12·02 (1·55–255·63) 0·037
Other 2·62 (0·59–11·80) 0·202
Overall <0·0001
Year of onset of paralysis 1·37 (1·11–1·69) 0·003
Data used are taken from the 60-day follow-up case investigation and include 
only virologically conﬁ rmed cases of poliomyelitis (wild-type or vaccine associated; 
n=1310). Akaike’s information criterion=904. EPI=Expanded Programme on 
Immunization.
Table 2: Multiple logistic regression analysis of factors associated with 
children younger than 15 years with poliomyelitis reporting at least 
one dose of oral poliovirus vaccine from routine immunisation or 
supplementary immunisation programmes
Panel: Research in context
Systematic review
We searched PubMed, with no date limits set, for articles published in English with the 
search terms “poliomyelitis AND Nigeria”, “bivalent oral poliovirus vaccine”, and 
“population immunity”. We used the reference lists of related articles to identify other 
important studies. The last search was done in June, 2013. Clinical eﬃ  cacy of monovalent 
oral poliovirus vaccine 1 (mOPV1) in 2008 in Nigeria was higher than trivalent oral 
poliovirus vaccine (tOPV), and tOPV eﬃ  cacy was higher in the south of Nigeria than the 
north, although the latter ﬁ ndings were non-signiﬁ cant.10 Serological responses to 
bivalent oral poliovirus vaccine (bOPV) have been documented in India and Nigeria 
(combined with tOPV) and clinical eﬃ  cacy recorded in Pakistan and Afghanistan.11–13 
Findings from these studies showed bOPV was non-inferior to mOPV against serotypes 1 
and 3. No studies so far have estimated bOPV clinical eﬃ  cacy in Nigeria. Quarterly 
estimates of vaccine coverage and social mobilisation data collected by house to house 
visits have been collated for high-risk states by PolioInfo.14 AFP surveillance data and 
poliomyelitis incidence have been recorded by WHO and published in the Weekly 
Epidemiological Record.3
Interpretation
In our study, we found greater eﬃ  cacy of mOPV and bOPV compared with tOPV in 
Nigeria, along with diﬀ erences in vaccine eﬃ  cacy between northern and southern 
regions, potentially resulting in the need for more doses to protect children in high-risk 
areas. We also noted a recent drop in the rate of refusals, although this remains 
unacceptably high, and we have provided strong evidence for the importance of 
community engagement if poliomyelitis is to be eradicated. Despite achieving the 
highest population immunity ever recorded in Nigeria, there are still substantial 
heterogeneities in vaccine coverage. In 20% of LGAs in high-risk areas fewer than half 
of children under 3 years of age were protected, which explains the continued 
occurrence of cases.
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and bOPV are more eﬀ ective than tOPV. We compared a 
subset of our population immunity results with those 
derived from a seroprevalence survey in Kano 
metropolitan area during 2011 (appendix).26 Estimated 
vaccine-induced immunity against serotypes 1 and 3 in 
selected LGAs in Kano was markedly lower than 
seroprevalence among children from these same LGAs 
attending outpatient clinics at Murtala Mohammed 
Specialist Hospital (p<0·0001). This ﬁ nding is probably a 
result of exposure to wild-type virus or secondary 
exposure to vaccine virus, diﬀ erences in the study 
populations, and, potentially, the tendency for case-
control studies to underestimate eﬃ  cacy when cases and 
controls diﬀ er in their exposure to poliovirus. Despite 
these diﬀ erences, the immunity estimates showed good 
correlation (Spearman’s rank test, ρ=0·61 and 0·53 for 
serotypes 1 and 3).
There are probably gaps in immunity not captured by 
this study (ie, areas that do not report AFP cases) and this 
is likely to be an issue in politically unstable regions or 
hard-to-reach communities. However, population 
immunity estimated using dose reporting during AFP 
surveillance was a good predictor of incidence, validating 
the use of these data in deriving these values. The risk of 
a case occurring in a given LGA was lower if that area 
had recorded a case in the previous 12 months, perhaps 
as a result of natural immunity following local circulation 
of poliovirus.
Nigeria holds the key to poliomyelitis eradication in 
Africa and possibly the world. There were substantial 
improvements in campaign coverage during 2012, as 
shown by the increasing number of LGAs accepted at a 
target of 80% coverage according to lot quality assurance 
sampling,8 and as shown in the lower case burden 
during 2013 (49 cases between Jan 1 and Oct 15, 2013).27 
However, continued campaign management problems 
and security challenges threaten to stall eradication 
attempts. The factors driving the sustained transmission 
of poliovirus in Nigeria—for example, continued 
refusals, lower vaccine eﬃ  cacy, and instability in worst-
aﬀ ected areas—can be overcome through sustained 
commitment from the highest level of government right 
through to the vaccinator on the streets. Children in 
northern Nigeria need additional OPV doses as an 
urgent priority, and improvement of vaccine acceptance 
will be the key to the programme’s success. The 
introduction of inactivated poliovirus vaccine might help 
to sustain immunity against serotype 2, while 
accelerating the eradication of the remaining 
type 1 and 3 wild polioviruses. Our results highlight the 
fundamental need for community engagement and 
education and the substantial beneﬁ ts in utilising the 
media and local leaders to positively promote 
poliomyelitis vaccination and educate mothers. The 
prospects for global eradication are positive as Nigeria 
moves towards eliminating poliomyelitis in the last 
remaining reservoir of infection in Africa.
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